Aug 5, 2026 06:47AM
May 6, 2026 06:34AM
Apr 15, 2026 03:34PM
Feb 25, 2026 12:03PM
Feb 25, 2026 07:25AM
Feb 14, 2026 10:00AM
Dec 17, 2025 02:14AM JPMorgan Upgrades Recursion Pharmaceuticals (RXRX ) to Overweight
Nov 5, 2025 06:38AM
Sep 8, 2025 07:01AM
Aug 5, 2025 06:38AM
Jul 28, 2025 07:00AM
Jul 8, 2025 08:03AM
Jul 3, 2025 04:19AM
Jun 16, 2025 07:35AM Recursion Pharmaceuticals (RXRX) PT Lowered to $5 at Morgan Stanley
Jun 10, 2025 06:21AM
Jun 6, 2025 10:01AM
May 6, 2025 03:18PM
May 6, 2025 05:40AM
May 5, 2025 06:31AM
Apr 16, 2025 08:42AM
Apr 8, 2025 08:04AM Recursion Pharmaceuticals (RXRX) Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
Mar 18, 2025 08:03AM
Feb 28, 2025 02:06PM
Feb 28, 2025 06:36AM
Feb 18, 2025 11:10AM
Feb 5, 2025 05:27PM
Jan 7, 2025 09:15AM
Dec 20, 2024 05:00AM Key takeaways from the 2024 BofA AI Conference
Nov 20, 2024 03:13PM
Nov 13, 2024 09:09AM
Nov 12, 2024 04:55PM
Nov 7, 2024 04:32PM
Oct 22, 2024 08:03AM
Oct 2, 2024 02:17PM
Oct 2, 2024 08:02AM Recursion Pharmaceuticals (RXRX) Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphom
Sep 4, 2024 07:12AM
Sep 3, 2024 03:00PM
Sep 3, 2024 02:54PM
Sep 3, 2024 11:50AM
Sep 3, 2024 08:19AM
Sep 3, 2024 08:00AM
Aug 8, 2024 07:41AM Recursion Pharmaceuticals (RXRX) to Merge with Exscientia (EXAI)
Aug 8, 2024 07:37AM
Jul 9, 2024 05:17AM
Jun 27, 2024 05:45AM
Jun 26, 2024 04:56PM
Jun 26, 2024 04:07PM
Jun 26, 2024 08:59AM

435,718 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All